Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Fulgent Genetics, |
RCV000764105 | SCV000895073 | uncertain significance | Guillain-Barre syndrome, familial; Hereditary liability to pressure palsies; Roussy-Lévy syndrome; Charcot-Marie-Tooth disease and deafness; Charcot-Marie-Tooth disease, type IA; Dejerine-Sottas disease | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV000537684 | SCV000636224 | uncertain significance | Charcot-Marie-Tooth disease, type I | 2018-09-20 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with lysine at codon 160 of the PMP22 protein (p.Glu160Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with PMP22-related disease. ClinVar contains an entry for this variant (Variation ID: 462781). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |